MedStar Health continues to offer expert clinical care to and research treatment opportunities for patients with melanoma within an interdisciplinary network based at both at MedStar Washington Hospital Center and MedStar Georgetown University Hospital. The Network is tightly linked to the Melanoma Research Program at the Georgetown-Lombardi Comprehensive Cancer Center (one of 47 NCI Designated Comprehensive Cancer Centers in the US and the only such one in the District of Columbia). Our Melanoma team remains the most experienced and comprehensive group for the treatment of patients with all stages of melanoma in the Greater Washington, DC area.
MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center is now curing patients with high-risk and distant metastatic melanoma with FDA-approved and research immunotherapy treatments. Now the standard of care and the backbone for new research studies, these immunotherapies work by restoring the function of tumor specific immune cells inside the tumor, enabling the immune system to fight the cancer on its own.These approaches are not chemotherapy and therefore do not have the side effects traditionally associated with chemotherapy. Instead, side effects are all related to activation of the immune system and can be addressed without altering the effectiveness of the immunotherapy.
The MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center is the only National Cancer Institute (NCI)-designated comprehensive cancer center in the Washington, D.C. region.